OSAKA, Japan -Tuesday, April 11th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications with a high unmet medical need.

Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications. NuBiyota will receive an upfront payment and is eligible for success-based development, regulatory and commercial milestones and tiered royalties based on net sales. Further details of the agreement were not disclosed.

“We are excited to partner with NuBiyota as this collaboration reinforces Takeda’s long-term commitment to unmet medical need in gastroenterology and adds to our other microbiome-related partnerships,” said Asit Parikh, M.D., Ph.D., head of Take ... Read more »

SAINT-PREX, Switzerland-Thursday, April 6th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Ferring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals in 2015 and 2016 across four key pillars for focus and activity: People, Business Ethics, Environment and Community.

"We have taken a number of significant steps on our CSR journey, notably by integrating CSR into our business planning, hiring a dedicated senior director to drive our global approach, and signing on to the United Nations Global Compact (UNGC),” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “I am proud of our progress to date, and look forward to embarking on the next phase.”

In line with the requirements of the UNGC, Ferring’s 2015-2016 review highlights the contribution that Ferring is making to support the United Nations Sust ... Read more »

BAD HOMBURG, Germany -Mardi 11 Avril 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Fresenius Medical Care AG & Co. KGaA ("the company" or "Fresenius Medical Care"), the world's largest provider of dialysis products and services, announced that it has filed the annual report 2016 under form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company's website www.freseniusmedicalcare.com in the "Investors" section as well as at the SEC's website, www.sec.gov.

A hard copy of Fresenius Medical Care's annual report on form 20-F including the complete audited financial statements may be obtained from the company free of charge upon request to the company's Investor Relations department by email at ir@fmc-ag.com.

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regu ... Read more »

Dividend of EUR 1.34 per A-share approved

LUXEMBOURG-Thursday, April 6th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- SES (Euronext Paris:SESG) (LuxX:SESG) held its Annual General Meeting (AGM) today in Betzdorf, Luxembourg.

The shareholders approved all proposed resolutions, notably the company's 2016 accounts and the proposed dividend of EUR 1.34 per A-share, which will be paid to shareholders on 26 April 2017.

Shareholders elected Kaj-Erik Relander, entrepreneur and independent advisor to different investment companies, to the Board of SES. They further renewed the mandates of Marc Beuls, Marcus Bicknell, Ramu Potarazu, Anne-Catherine Ries and Jean-Paul Zens for a new three-year term.

Following the shareholders’ meeting, the Board of Directors re-elected Mr Romain Bausch as Chairman as well as Mr François Tesch and Mr Jean-Paul Zens as Vice Chairmen.

The 2016 Annual Report is available for download at: http://www. ... Read more »

Controlled-release treatments can maximise efficiency and improve patient-adherence

SAINT-PREX, Switzerland-Monday, April 10th 2017 [ ME NewsWire ]

(BUSINESS WIRE) -- Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology Platform for the development of an injectable, controlled-release formulation of a peptide therapeutic.

Under the terms of the agreement, Alrise will conduct feasibility and scale-up studies with Ferring. Upon completion of the development work, Ferring will have the right to exercise its option and enter into a definitive agreement with Alrise to further develop and manufacture the formulation.

“Ferring aims to harness innovative technology platforms, such as Alrise’s microparticle-technology platform, in order to provide new, controlled-release formulations of pept ... Read more »